Shared Living Agreement. For NMDs who are remaining in their current placement at age 18, as well as those NMDs who are moving into a new xxxxxx family home or into a placement with a relative caregiver or Non Related Extended Family Member (NREFM), it is best practice for the NMD to enter into a Shared Living Agreement (SLA) with the caregiver or other roommates. The SLA process is optional for counties to use to assist in developing agreements that are similar to “house rules” between NMDs and providers or caregivers to assist both NMDs and providers/caregivers in transitioning to their new adult roles All County Letter Number 11-69 Page Sixteen and relationships and resolving conflicts about use of common space. The attached document provides guidelines that counties may use in developing a SLA. An SLA may also be appropriate for some SILP situations in which the NMD rents a room from a friend or stranger. See Attachment B. A new xxxxxx care placement option called THP-Plus-FC is created via W&IC section 11403.2(a)(3). This housing program is specifically for NMDs who remain in EFC as dependants of the court. This is a Title IV-E eligible placement. It will offer similar housing models and supportive services that are available in the current THP-Plus program. This placement option is not licensed by Community Care Licensing, but is required to be approved by the county. The CDSS is in the process of developing approval standards and operational procedures with input from the AB12 sponsors and stakeholders. All current and potential providers must be approved using these statewide approval standards. Due to these current efforts, the implementation of the THP-Plus-FC program will be delayed. The CDSS anticipates the standards will be available by February 2012 and implementation will begin mid 2012. However, counties are encouraged to continue developing their programs, including contracting with providers, to the extent possible, collaborating with surrounding counties and outreaching to youth. Counties are not required to revise the county plans or Letters of Intent for the Transitional Housing Programs. A separate ACL will be released regarding THP-Plus-FC, including provider information and approval standards. For NMDs who reside in a different county than their jurisdiction, the county of jurisdiction retains case management, and financial responsibility for NMDs. The county of residence, or tribal social worker, may agree to provide courtesy supervision of the case and ac...

Shared Living Agreement. After you have arrived there will be some time to settle into your new home and get to know your housemates. This will be the best time to talk about and complete your Shared Living Agreement. It is helpful to have these conversations early as it can be a great opportunity to get to know who you’re living with better and discuss expectations about living together. Coming to an agreement may mean making compromises, so make sure you are ready to make some sacrifices. It is important that everyone is comfortable living in their accommodation. When you are ready to complete your Shared Living Agreement follow the below link: The first section of the agreement is the set of non-flexible regulations that you need to read and agree to as a household. You will be agreeing to:

Shared Living Agreement. Choice or the nominated Management Partner may require the Tenant to sign a shared living agreement which sets out the Tenant’s duties and responsibilities whilst living as a tenant in a supported housing scheme and in order to facilitate good management of the scheme by the nominated Management Partner. In tenancies where a shared living agreement is required to be signed, the Tenant agrees to comply with the conditions and requirements contained therein. Choice or the applicable nominated Management Partner will provide a copy to the Tenant upon signing the Tenancy Agreement and explain the Tenant’s rights and responsibilities. Any revision or amendment to the provisions of the shared living agreement will only be permitted following consultation with all Tenants at the scheme. Tenants in a supported housing scheme which is classed as a House in Multiple Occupation (‘HMO’) must observe a strict no smoking policy.

Related to Shared Living Agreement

Client Agreement We are not required to enter into a written agreement complying with the Code relating to the services that are to be provided to you.
Transition Agreement In the event of termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos pursuant to Section 12.2.1, or with respect to one (1) or more countries or other jurisdictions by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i), Galapagos and AbbVie shall negotiate in good faith the terms and conditions of a written transition agreement (the “Transition Agreement”) pursuant to which AbbVie and Galapagos will effectuate and coordinate a smooth and efficient transition of relevant obligations and rights to Galapagos as reasonably necessary for Galapagos to exercise the licenses granted pursuant to Sections 12.6 or 12.7 after termination of this Agreement (in its entirety or with respect to one (1) or more countries or other jurisdictions, as applicable) as and to the extent set forth in this Article 12. For clarity, AbbVie shall not be required to Manufacture or have Manufactured the Molecules or Products by or on behalf of Galapagos as part of the Transition Agreement. 12.8.1 The Transition Agreement shall provide that in the event of a termination of this Agreement in its entirety by AbbVie pursuant to Section 12.3.2 or by Galapagos in its entirety pursuant to Section 12.2.1, AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Documentation then Controlled by AbbVie or its Affiliates or Sublicensees and in its/their name applicable to the Products in the Territory that are the subject of an exclusive license grant in Section 12.6.1(iii); (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (iv) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of pre-clinical Development activities, Clinical Studies or Manufacturing activities for the Products, including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party. 12.8.2 The Transition Agreement shall provide that in the event of a termination of this Agreement with respect to a country or other jurisdiction by AbbVie pursuant to Section 12.3 or by Galapagos pursuant to Section 12.2.2(i) (but not in the case of any termination of this Agreement in its entirety), AbbVie shall: (i) where permitted by Applicable Law, transfer to Galapagos all of its right, title, and interest in all Regulatory Approvals owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, which Regulatory Approvals are solely applicable to the relevant country or jurisdiction and the Products that are the subject of an exclusive license grant in Section 12.7, as such Regulatory Approvals exists as of the effective date of such termination of this Agreement with respect to such relevant country or jurisdiction; provided, that AbbVie retains a license and right of reference under any Regulatory Approval transferred pursuant to this clause as necessary or reasonably useful for AbbVie to Commercialize Products in the Territory, Develop Molecules or Products in support of such Commercialization, or Manufacture Molecules or Products in support of such Development or Commercialization; (ii) notify the applicable Regulatory Authorities and take any other action reasonably necessary to effect the transfer set forth in clause (i) above; (iii) grant Galapagos a right of reference to all Regulatory Documentation then owned by, or in the name of, AbbVie or its Affiliates or Sublicensees, and which Regulatory Documentation is not transferred to Galapagos pursuant to clause (i) above, and is necessary or reasonably useful for Galapagos, any of its Affiliates or sublicensees to Develop or Commercialize in the terminated country or jurisdiction the Product(s) that are the subject of the license grant in Section 12.7 as such Regulatory Documentation exists as of the effective date of such termination of this Agreement with respect to such terminated country or jurisdiction; (iv) if requested by Galapagos and unless expressly prohibited by any Regulatory Authority, transfer control to Galapagos of all Clinical Studies specific to such terminated country(ies) being Conducted by AbbVie or its Affiliates or Sublicensees as of the effective date of termination and continue to Conduct such Clinical Studies, at Galapagos’ cost, for up to […***…] ([…***…]) months to enable such transfer to be completed without interruption of any such Clinical Study; provided, that (a) Galapagos shall not have any obligation to continue any Clinical Study unless required by Applicable Law, and (b) with respect to each Clinical Study for which such transfer is expressly prohibited by the applicable Regulatory Authority, if any, AbbVie shall continue to Conduct such Clinical Study to completion, at Galapagos’ cost; and (v) assign (or cause its Affiliates or Sublicensees to assign) to Galapagos all agreements with any Third Party with respect to the Conduct of Clinical Studies specific to such terminated country(ies), including agreements with contract research organizations, clinical sites, and investigators, unless, with respect to any such agreement, (a) Galapagos declines such assignment, or (b) such agreement (1) expressly prohibits such assignment, in which case AbbVie shall cooperate with Galapagos in reasonable respects to secure the consent of the applicable Third Party to such assignment, or (2) covers products covered by Patents Controlled by AbbVie or any of its Affiliates in addition to the Products, in which case AbbVie shall, at Galapagos’ sole cost and expense, cooperate with Galapagos in all reasonable respects to facilitate the execution of a new agreement between Galapagos and the applicable Third Party.
AMENDING OPERATING AGREEMENT This Agreement may only be amended by an affirmative vote or consent of all Members.
Services Agreement “Services Agreement” shall mean any present or future agreements, either written or oral, between Covered Entity and Business Associate under which Business Associate provides services to Covered Entity which involve the use or disclosure of Protected Health Information. The Services Agreement is amended by and incorporates the terms of this BA Agreement.
Operating Agreement The Borrower will not amend, modify, waive or terminate any provision of its operating agreement without the prior written consent of the Administrative Agent.
License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.
Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.
One Agreement This Agreement and any related security or other agreements required by this Agreement, collectively: (a) represent the sum of the understandings and agreements between the Bank and the Borrower concerning this credit; (b) replace any prior oral or written agreements between the Bank and the Borrower concerning this credit; and (c) are intended by the Bank and the Borrower as the final, complete and exclusive statement of the terms agreed to by them. In the event of any conflict between this Agreement and any other agreements required by this Agreement, this Agreement will prevail.
Master Services Agreement This Agreement is a master agreement governing the relationship between the Parties solely with regard to State Street’s provision of Services to each BTC Recipient under the applicable Service Modules.
Letter Agreement The Company shall have entered into the Letter Agreement on terms satisfactory to the Company.

Shared Living Agreement Sample Clauses

Filter & Search

Related Clauses

Parent Clauses

Related to Shared Living Agreement